Sono Tek Corp (SOTK) · Oct 14, 2026 · Earnings
Miss — Q2 revenue $5.23M vs ~$5.54M consensus; diluted EPS $0.02 vs ~$0.04
Sono-Tek’s earnings miss revenue and EPS estimates, while medical-device demand drove first-half growth and margins expanded sharply.
Sono-Tek is shifting toward higher-value, production-scale ultrasonic coating systems, with medical devices becoming the growth engine while clean-energy demand remains exposed to policy changes. Its prior-quarter update had already identified medical momentum and clean-energy weakness as the central business split.
| Metric | Q2 FY2027 | Q2 FY2026 | Change / expectation |
|---|---|---|---|
| Net sales | $5.23M (Income Statement) | $5.16M (Income Statement) | +1%; ~$5.54M published consensus |
| Gross profit | $2.77M (Income Statement) | $2.59M (Income Statement) | +7% |
| Gross margin | 53% (Financial Highlights) | 50% (Financial Highlights) | +3 percentage points |
| Operating income | $0.38M (Income Statement) | $0.42M (Income Statement) | -9% |
| Net income | $0.37M (Income Statement) | $0.42M (Income Statement) | -14% |
| Diluted EPS | $0.02 (Income Statement) | $0.03 (Income Statement) | ~$0.04 published consensus |
| First-half net sales | $10.89M (Financial Highlights) | $10.30M (Financial Highlights) | +6% |
| First-half operating income | $1.28M (Financial Highlights) | $0.90M (Financial Highlights) | +41% |
The quarter missed the external bar despite a solid first half. Q2 revenue was essentially flat year over year and below published estimates, while diluted EPS fell to $0.02 from $0.03 and also trailed the roughly $0.04 consensus. The miss is not a collapse in the business, but it shows that the timing of higher-value system shipments is still making quarterly results uneven. 〔0〕
The underlying mix improved materially. First-half gross margin expanded to 55% from 51%, and operating income rose 41% despite only 6% sales growth. That supports the company’s transition toward more complex production platforms, but the benefit is showing up more clearly over six months than in this individual quarter. 〔1〕
Medical-device demand is now doing the heavy lifting. First-half medical sales surged 289% to $7.05 million, led by balloon-coating and specialty stent-coating systems, while first-half multi-axis sales rose 50%. The company says customers are moving from development into commercial manufacturing, which is a more durable demand signal than one-off research orders.
Clean energy remains the offsetting drag. Alternative-energy sales fell 85% in the first half, reflecting policy and spending shifts in green hydrogen, electrolysis and fuel-cell applications. That weakness was already part of the standing story, so the new information is mainly how strongly medical growth is compensating for it—not a clean-energy recovery. 〔2〕
Management left the full-year outlook unchanged. The company maintained its previously communicated expectation of flat to modest full-year revenue growth, citing large production-platform orders whose shipment timing can create quarter-to-quarter volatility. That is reassuring relative to a potential cut, but it does not repair the Q2 estimate miss. 〔3〕
Bottom line: This was a quarterly earnings miss, but the six-month picture is improving because medical-device demand is scaling into higher-margin production systems. The event matters more as confirmation of the business mix shift than as evidence of accelerating near-term revenue growth.
Fiscal Q3 earnings report, expected January 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!